Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study
- 1 April 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (4) , e2501250
Abstract
PURPOSE: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with urothelial (UC) or ovarian/fallopian tube cancer (OC/FTC) with ERBB2/3 alterations treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS: Eligible patients had advanced cancer, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with ERBB2/3 alterations, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. Simon's two-stage design is based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS: Patients with UC (n = 28) or OC/FTC (n = 25) with ERBB2/3 alterations were enrolled from March 2017 to June 2023. In the UC cohort, the DC and OR rates were 37% (90% CI, 24 to 100) and 25% (95% CI, 11 to 45), respectively. The null hypothesis of 15% DC rate was rejected ( P = .005). In the OC/FTC cancer cohort, the DC and OR rates were 23% (90% CI, 9 to 100) and 8% (95% CI, 1 to 26), respectively. The null hypothesis of 15% DC rate was not rejected ( P = .35). Six patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to treatment. CONCLUSION: The combination of P + T met prespecified criteria to declare a signal of activity in patients with UC with ERBB2/3 alterations, but not in patients with OC/FTC.Keywords
This publication has 56 references indexed in Scilit:
- A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid TumorsJAMA Oncology, 2025
- Characterizing multi‐PIK3CA mutations across cancer types: Toward precision oncologyCancer Medicine, 2024
- Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder CancerTargeted Oncology, 2024
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancerJournal of Cancer Research and Clinical Oncology, 2022
- Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTargeted Oncology, 2020
- Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTargeted Oncology, 2020
- A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinomaCancer, 2009
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989